| Target Professions: | DO, MD, Nurse Practitioner, Physician Associate/Assistant |
| Target Specialties: | Endocrinology |
| Credits Available: | 4.75 hours of AMA PRA Category 1 Credit™ |
Patients who are living with obesity or overweight may seek care with an endocrinologist for other comorbidities, some of which may be directly linked to their weight. Weight reduction and management using pharmacotherapy, including GLP-1 RAs, can be a useful strategy to help patients improve not only their weight but also their metabolic health. Through this program, endocrinologists will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs, especially if they have other comorbidities, and apply clinical trial findings to everyday patient care. They will also enhance their understanding of strategies which can improve both patient adherence and payor authorization/approval.
Before jumping into the activity content, reflect on what your current knowledge of pharmacotherapies used to optimize metabolic health and how therapy choices vary based on comorbidities in patients who are living with overweight or obesity.
This module will focus on the clinical benefits of GLP-1 receptor agonists and GLP-1/ GIP receptor agonists and strategies for managing common adverse events.
This module will provide a thorough overview of using GLP-1 RAs to optimize metabolic health in patients who are living with obesity or overweight and have other endocrine conditions.
This module focuses on patient-centered approaches for education and follow up regarding GLP-1 and GLP-1/GIP receptor agonists. Learn proven strategies for improving GLP-1 and GLP-1/GIP receptor agonist adherence and long-term outcomes.
Review what you have learned about obesity, metabolic optimization, and using GLP-1 RAs in patients to improve their health in the context of comorbidities. This short assessment reviews the program’s content and provides new information to enhance your clinical practice.
This Live Group Discussion will focus on a case of a 36-year-old female with a history of obesity, PCOS, and recently diagnosed mild MASLD. We will also address any questions you may have regarding the baseline and final assessments and the self-study modules.
Meet P.D., a 42-year-old female with a lifelong history of overweight/obesity, recently diagnosed MASLD, and pre-existing chronic, poorly managed depression.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with obesity and endocrine disorders.
This Live Group Discussion will focus on a case of a 60-year-old male with a history of obesity, CKD stage I, and hypertension which is stable on an ACE inhibitor. We will also review your submissions on the Patient Case Challenge and Action Plans.
